IGC Pharma (IGC) Equity Income (2011)
IGC Pharma's (IGC) quarterly Equity Income came in at -$33588.0 in Q4 2011, down 230.02% quarter-over-quarter from $25832.0 in Q3 2011.
Powered by 
Analysis
IGC Pharma (IGC) Equity Income (2011) Analysis & Trends
IGC Pharma (IGC) has reported Equity Income for 1 consecutive years, with -$33588.0 the latest figure, recorded in Q4 2011.
- On a quarterly basis, Equity Income changed N/A year-over-year to -$33588.0 in Q4 2011; TTM through Sep 2012 was -$33588.0, a N/A change from a year earlier, with the FY2017 full-year figure at $317742.0, changed N/A from the prior year.
- Equity Income was -$33588.0 for Q4 2011 at IGC Pharma, down from $25832.0 in the prior quarter.
- Over five years, Equity Income peaked at $36219.0 in Q2 2011 and troughed at -$33588.0 in Q4 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | IGC Pharma | 27.77 Mn | 27.51 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2011 | -33,588.00 |
| Sep 30, 2011 | 25,832.00 |
| Jun 30, 2011 | 36,219.00 |